{"title":"[Multimodal Treatments for Spinal Cord Glioma: Up to Date].","authors":"Toshiki Endo, Yoshiharu Takahashi, Taketo Nishizawa, Tatsuya Sasaki","doi":"10.11477/mf.030126030530010189","DOIUrl":null,"url":null,"abstract":"<p><p>This study reviews the diagnostic criteria and treatment strategies for spinal malignant gliomas, particularly glioblastoma with <i>IDH</i>-wildtype and diffuse midline gliomas with H3-K27 alteration, according to the World Health Organization 2021 classification. Surgical resection remains challenging owing to the diffuse nature of these tumors. Even with the Stupp regimen(temozolomide and radiotherapy), the prognosis remains poor, with an average survival of 12 months. New therapeutic approaches, such as photodynamic therapy, and targeted molecular therapies, such as ONC201 and anlotinib, are currently under investigation. These innovations may improve the outcome of patients with malignant spinal gliomas, highlighting the importance of molecular profiling and collaborative research efforts to advance treatment.</p>","PeriodicalId":35984,"journal":{"name":"Neurological Surgery","volume":"53 1","pages":"189-198"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurological Surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.11477/mf.030126030530010189","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
This study reviews the diagnostic criteria and treatment strategies for spinal malignant gliomas, particularly glioblastoma with IDH-wildtype and diffuse midline gliomas with H3-K27 alteration, according to the World Health Organization 2021 classification. Surgical resection remains challenging owing to the diffuse nature of these tumors. Even with the Stupp regimen(temozolomide and radiotherapy), the prognosis remains poor, with an average survival of 12 months. New therapeutic approaches, such as photodynamic therapy, and targeted molecular therapies, such as ONC201 and anlotinib, are currently under investigation. These innovations may improve the outcome of patients with malignant spinal gliomas, highlighting the importance of molecular profiling and collaborative research efforts to advance treatment.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
